---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008277"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:07:50.642379+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports 39% ORR in Cohort 2 of [212Pb]VMT-α-NET trial; safety cleared at 6.0 mCi

## Summary
- Updated interim data from Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-expressing NETs at ASCO-GI.
- Objective response rate of 39% (9/23) in Cohort 2 per RECIST v1.1; 8 confirmed, 1 pending.
- 76% (19/25) of evaluable patients without progression and alive; deepening of best response seen in 7 patients.
- DLT assessment completed for Cohort 3 (6.0 mCi); cleared to enroll more; one additional patient already treated.
- No DLTs, treatment-related discontinuations, or serious renal complications across 56 patients.

## SEC filing metadata
- accession: 0001193125-26-008277
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526008277/0001193125-26-008277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526008277/catx-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008277
- JSON: https://secwatch.observer/filing/0001193125-26-008277.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.